内部人交易记录
其他尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Explore the detailed record of transactions filed by Doyle Mittie. Officer active across 1 company, notably Avalo Therapeutics, Inc.. Cumulatively, 23 reports have been logged. Split: 0 buy · 9 sells. Total volume traded: €139k. History available since 10 December 2025. The latest transaction was disclosed on 28 August 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Doyle Mittie
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报23 总计
679 股@ US$8.040.0005% mcap1.1% 占其流量Common StockSEC:0001918845-26-000031:0
679 股@ US$20.000.0013% mcap2.6% 占其流量Common StockSEC:0001918845-26-000031:1
1,000 股@ US$12.650.0012% mcap2.6% 占其流量Common StockSEC:0001918845-26-000029:0
1,000 股@ US$20.000.0019% mcap4.1% 占其流量Common StockSEC:0001918845-26-000029:1
679 股@ US$8.040.0005% mcap1.2% 占其流量Common StockSEC:0001918845-26-000026:0
679 股@ US$20.000.0013% mcap3.0% 占其流量Common StockSEC:0001918845-26-000026:1
1,000 股@ US$12.650.0012% mcap2.9% 占其流量Common StockSEC:0001918845-26-000024:0
1,000 股@ US$20.000.0019% mcap4.6% 占其流量Common StockSEC:0001918845-26-000024:1
2,875 股Common StockSEC:0001918845-26-000022:0
1,779 股Common StockSEC:0001918845-26-000022:1
4,654 股Common StockSEC:0001918845-26-000022:2
1,450 股Common StockSEC:0001918845-26-000020:0
1,450 股Common StockSEC:0001918845-26-000020:1
1,084 股Common StockSEC:0001918845-26-000018:0
679 股@ US$8.040.0005% mcap33.4% 占其流量Common StockSEC:0001918845-26-000016:0
679 股@ US$16.000.0010% mcap66.6% 占其流量Common StockSEC:0001918845-26-000016:1
43,500 股0Common StockSEC:0001918845-26-000014:0
3,970 股@ US$18.012251.8% 占其流量Common StockSEC:0001918845-26-000008:1
3,970 股@ US$12.6536.4% 占其流量Common StockSEC:0001918845-26-000008:0
679 股@ US$8.043.5% 占其流量Common StockSEC:0001918845-26-000006:0
679 股@ US$16.007.0% 占其流量Common StockSEC:0001918845-26-000006:1
19,500 股@ US$12.6561.8% 占其流量Common StockSEC:0001918845-26-000004:0
1,013 股@ US$4.101.0% 占其流量Common StockSEC:0001470831-25-000412:0
About Doyle Mittie
Doyle Mittie is Chief Medical Officer at Avalo Therapeutics, Inc. This declarant has filed 17 filings in total. In the sampled recent filings, between 2025-12-12 and 2026-07-29, the sell volume is EUR 98216 and the modal transaction nature is Levée d'options.